Results
As shown in Table 1, the overall characteristics of the two groups of
patients were well matched at baseline. There were also no significant
differences in indexes derived from CGM between the groups at baseline.
CGM showed that 24-hour mean glucose and postprandial glucose after each
meal decreased significantly after treatment with tofogliflozin in
patients receiving or not receiving DPP-4 inhibitors (Fig. 1A and B, and
Table 2). Time in range increased significantly after treatment in both
the group receiving DPP-4 inhibitors (from 54.9% ± 27.8% to 78.2% ±
22.2%, respectively; P = 0.0120) and the group not receiving
them (from 65.5% ± 33.9% to 83.9% ± 20.2%, respectively; P =
0.0276), and time above range significantly decreased in both groups
(Table 2).
After treatment with tofogliflozin, the SD of 24-hour glucose
significantly decreased in the group receiving DPP-4 inhibitors (from
40.80 ± 17.89 mg/dL to 29.70 ± 10.23 mg/dL, P = 0.0108; Table 2)
but did not significantly change in the group not receiving DPP-4
inhibitors (P=0.1028). In patients
receiving DPP-4 inhibitors, MAGE was significantly reduced (from 98.8 ±
41.6 mg/dL to 70.9 ± 29.3 mg/dL, P = 0.0066), as was MPPGE (from
77.2 ± 41.8 mg/dL to 63.8 ±3 2.1 mg/dL, P = 0.0378); however, both these
indexes of glycemic variability were unchanged in patients not receiving
DPP-4 inhibitors (Table 2).